Get notified when SHPH files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Going Concern (worsened) — Baseline stated existing cash and October 2024 financing insufficient; current states three 2025 equity raises plus revolving note still insufficient for twelve months.
- Material Weakness (improved) — Material weaknesses persist but count reduced from five to three; two prior weaknesses remediated.
SHPH pivots to AI drug-discovery platform, winds down clinical trials, burns $11.7M
Filed March 31, 2026 · Period ending December 31, 2025 · Compared to 10-K Feb 26, 2025 · ~2 min read
Key Changes
-
high
Acquired Molecule.ai AI platform for $10.1M (owes $6.4M deferred), terminated Ropidoxuridine Phase II trials, and cut headcount 78% (9→2 employees) in November 2025 strategic pivot.
Business: Molecule.ai acquisition verify on EDGAR → -
high
Raised $11.8M across three equity offerings in 2025 but ended year with $0.3M cash and $7.5M working capital deficit; going-concern doubts persist despite March 2026 $3.4M raise.
MD&A: Liquidity verify on EDGAR → -
high
Paid IR Agency $3.5M (30% of operating expenses) for investor relations in two short-term contracts; allocated $1.25M of March 2026 raise proceeds to marketing.
MD&A: IR Agency contracts verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (PXED 10-Q) is open in full — no account needed.
Partner
Trade SHPH commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 3, 2026 · How we verify